~
This is very good news for medical marijuan, according to a policy statement released Monday.
 
"The AAP strongly supports research and development of pharmaceutical cannabinoids and supports a review of policies promoting research on the medical use of these compounds," the AAP statement reads. To that end, the group recommends that the DEA reschedule marijuana from a Schedule I controlled substance to Schedule II.
 
Under the Controlled Substances Act, the U.S. has five "schedules" for drugs and chemicals that can be used to make drugs. Schedule I is reserved for drugs that the DEA considers to have the highest potential for abuse and no "currently accepted medical use." Marijuana has been classified as Schedule I for decades, along with other substances like heroin and LSD. While a lower schedule for marijuana would not make it legal, it could ease restrictions on researching the drug.
 
While the AAP added that it does not support the legalization of marijuana, citing the potential harms to children and adolescents, it did say that it "strongly" supports the decriminalization of marijuana use and encourages pediatricians to "advocate for laws that prevent harsh criminal penalties for possession or use of marijuana."
 
"A focus on treatment for adolescents with marijuana use problems should be encouraged, and adolescents with marijuana use problems should be referred to treatment," the statement said.
 
Monday's statement is the first change to AAP policy on the issue since 2004. At that time, the group did not request a schedule change.
 
The DEA is the federal agency that is primarily responsible for regulating controlled substances like marijuana. But the Food and Drug Administration, along with the National Institute on Drug Abuse, provides the DEA with recommendations about the appropriate level of restriction for various illicit substances.
 
The FDA is already engaged in a review of the medical evidence surrounding the safety and effectiveness of marijuana. The evaluation was initiated due to a request from the DEA, following a number of citizens' petitions asking for a review. According to the Controlled Substances Act, the government must consider eight factors when deciding the schedule under which a substance should be classified. These include its potential for abuse, the state of current scientific knowledge about the substance and its psychic or physiological dependence liability.
 
The FDA could not confirm to The Huffington Post how long the review process takes, but expressed support for AAP's move.
 
"FDA can’t comment on the suggestion to change the schedule for marijuana, as the latest FDA review of the issue -- known as the 8-factor analysis -- is currently ongoing, FDA press officer Jeff Ventura said Monday. "However, FDA agrees with the call by the AAP for rigorous scientific research into the uses of marijuana ... [and] supports those in the medical research community who seek to study marijuana."
 
The DEA has made previous requests, in 2001 and 2006, to the FDA for an evaluation of marijuana. Those requests were the results of public petitions requesting a rescheduling, FDA Deputy Director Doug Throckmorton explained in testimony delivered during a congressional hearing last year. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. The FDA cited insufficient available research about marijuana's effectiveness in treating a number of ailments.
 
While the FDA hasn't advocated for legalization of the drug, it said in a 2014 update to its guidelines on marijuana that it is "aware that there is considerable interest in its use to attempt to treat a number of medical conditions, including, for example, glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders."
 
Matt Ferner ~ January 27, 2015
 
 
February 24, 2020

Pot Use Among U.S. Seniors Nearly Doubled…

Americans may want to rethink the stereotype of the pot-loving teen: More U.S. seniors are using the drug now than…
February 24, 2020

Bahamas Asks Public to Decide on Cannabis…

The Bahamas National Commission on Marijuana expects to complete a crucial public survey on whether cannabis should be legalized by…
February 24, 2020

Canadian Teenagers Stopped Smoking Weed After Legalization…

A new report from Statistics Canada adds to a growing body of evidence that marijuana legalization dissuades adolescent use.
February 24, 2020

USDA recommends ‘creative solution’ for transporting hemp…

Hauling hemp can be risky for drivers even though it’s now legal to grow it, process it and sell it…
February 21, 2020

The best new cannabis strains to grow…

Here are the best new cultivars and clones to grow in 2020 -- selected based on interviews with the world’s…
February 21, 2020

Idaho farmers warn they’re losing money without…

Idaho is one of only three states that does not allow the cultivation of hemp, despite the federal government making…
February 21, 2020

Kentucky House passes medical marijuana bill after…

Kentucky’s state House on Thursday passed a measure that would legalize medical marijuana in the state after several unsuccessful earlier…
February 20, 2020

A new ‘hemp scanner’ determines level of…

A team of researchers have created a ‘hemp scanner’ that can determine the level of THC in cannabis plants instantly,…
February 20, 2020

Indonesian activist prepares ground for future cannabis…

A Jakarta-based activist is campaigning to change public perceptions and Indonesian policy so that patients suffering from chronic disease and…
February 20, 2020

The cannabis industry's next big threat: Hacks…

Experts are cautioning companies to shore up their security practices and for consumers to be mindful of opportunities that seem…
February 20, 2020

USDA Touts Hemp Industry’s Growth But Says…

The USDA report attempts to draw conclusions about the legal, logistical and economic challenges that might arise as US farmers…